Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer

National Taiwan University Hospital108 enrolled

Overview

The purpose of this study is to assess the overall response rate to Iressa as a first-line treatment in chemonaive patients with inoperable Non-Small Cell Lung Cancer (NSCLC)

The epidermal growth factor receptor (EGFR) is a promising target for anticancer therapy because it is expressed or highly expressed in a variety of tumors, including NSCLC.Furthermore, high levels of EGFR expression have been associated with a poor prognosis in lung cancer patients in several studies. EGFR-targeted cancer therapies are currently being developed; strategies include inhibition of the intracellular tyrosine kinase domain of the receptor by small molecules such as gefitinib (Iressa \[ZD1839\]; AstraZeneca, Wilmington, DE). Iressa is an orally active, selective EGFR tyrosine kinase inhibitor that blocks signal transduction pathways implicated in the proliferation and survival of cancer cells.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

108

Conditions

Non-Small Cell Lung Cancer

Interventions

IressaDRUG

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically or cytologically confirmed stage IIIB/IV NSCLC * No immediate need for palliative radiotherapy and No prior chemotherapy * age \> 20 Y/O * ECOG PS: 0 - 2 * ANC \>2000 * PLT \>100k * Hb \> 10 * total bilirubin \< 2.0 mg/dL * serum creatinine \< 2 mg/dl * SGPT and SGOT \< 2.5 ×ULN, alkaline phosphatase \< 5 ×ULN * life expectancy \>6mos. Exclusion Criteria: * If the patients have brain metastases or receive radiotherapy, the disease must be stable for more than 6 weeks after the last dose of radiotherapy * 2nd malignancies * Unable to swallow tablets * Patients (M/F) with reproductive potential not implementing adequate contraceptive measurements * Pregnant or lactating patients * Participation in other clinical trials within 30 days of study entry * Major systemic disease which in the investigator's opinion might confound the clinical trial

Locations (1)

Department of Oncology, National Taiwan University Hospital

Taipei, Taiwan

Outcomes

Primary Outcomes

The primary objective of this study is to assess the overall response rate to Iressa as a first-line treatment in chemonaive patients with inoperable Non-Small Cell Lung Cancer

Time frame: 2005~2007

Secondary Outcomes

To evaluate 1) Individual response rate 2) Time to progression 3) Overall survival (OS) at year1 4) Progression free survival (PFS) at year1 5) Toxicity

Time frame: 2005~2007

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.